TICKERNOMICS Sign up
Last Update: 2024-03-28 02:14:09
I-Mab ( IMAB ) https://www.i-mabbiopharma.com
1.84USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
China
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-41.40%
IMAB
SPY
32.74%
-96.05%
IMAB
SPY
92.93%
IMAB
0.00%
SPY
224.41%
IMAB
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
355.36
274.76
0.51
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.39
-14.72
1.06
-475.85
0.00
-0.16
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
170.49
101.54
171.28
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
-441.87
-393.33
0.00
Other Earnings and Cash Flow Stats:
I-Mab ( IMAB ) Net Income TTM ($MM) is 0.00
I-Mab ( IMAB ) Operating Income TTM ($MM) is 0.00
I-Mab ( IMAB ) Owners' Earnings Annual ($MM) is -718.81
I-Mab ( IMAB ) Current Price to Owners' Earnings ratio is -0.49
I-Mab ( IMAB ) EBITDA TTM ($MM) is 0.00
I-Mab ( IMAB ) EBITDA Margin is 171.28%
Capital Allocation:
I-Mab ( IMAB ) has paid 0.00 dividends per share and bought back -107.517475 million shares in the past 12 months
I-Mab ( IMAB ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
I-Mab ( IMAB ) Interest-bearing Debt ($MM) as of last quarter is 0
I-Mab ( IMAB ) Annual Working Capital Investments ($MM) are -2
I-Mab ( IMAB ) Book Value ($MM) as of last quarter is 336
I-Mab ( IMAB ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
I-Mab ( IMAB ) has 324 million in cash on hand as of last quarter
I-Mab ( IMAB ) has 91 million of liabilities due within 12 months, and long term debt 4 as of last quarter
I-Mab ( IMAB ) has 190 common shares outstanding as of last quarter
I-Mab ( IMAB ) has 0 million USD of preferred stock value
Academic Scores:
I-Mab ( IMAB ) Altman Z-Score is -14.79 as of last quarter
I-Mab ( IMAB ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
I-Mab ( IMAB ) largest shareholder is Diametric Capital, LP owning 122953 shares at 0.23 ($MM) value
(an insider) shares of I-Mab ( IMAB ) for the amount of $ on
0.10% of I-Mab ( IMAB ) is held by insiders, and 8.12% is held by institutions
I-Mab ( IMAB ) went public on 2020-01-17
Other I-Mab ( IMAB ) financial metrics:
FCF:0.00
Unlevered Free Cash Flow:-1765.59
EPS:-9.08
Operating Margin:170.49
Gross Profit Margin:101.54
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-512.88
Beta:0.00
Buffet's Owners Earnings:-718.81
Price to Owner's Earnings:-0.49
About I-Mab ( IMAB ) :
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.